Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today provided clinical updates and reported financial results for the first quarter ended March 31, 2013.
Clinical Updates
Interim results from the randomized GALAXY-1 Phase 2b/3 trial, which compares docetaxel with and without Synta’s investigational Hsp90 inhibitor ganetespib for the second-line treatment of advanced non-small cell lung cancer (NSCLC), will be presented at the American Society for Clinical Oncology (ASCO) in June 2013.
Help employers find you! Check out all the jobs and post your resume.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today provided clinical updates and reported financial results for the first quarter ended March 31, 2013.
Clinical Updates
Interim results from the randomized GALAXY-1 Phase 2b/3 trial, which compares docetaxel with and without Synta’s investigational Hsp90 inhibitor ganetespib for the second-line treatment of advanced non-small cell lung cancer (NSCLC), will be presented at the American Society for Clinical Oncology (ASCO) in June 2013.
Help employers find you! Check out all the jobs and post your resume.
